Effect of gemfibrozil on HDL-associated serum paraoxonase activity and lipoprotein profile in patients with hyperlipidaemia

Clinical Drug Investigation

Volumn 19, Issue 4, 2000, Pages 277-282

  Paragh, György ^a,b   Balogh, Zoltán ^a   Seres, Ildikó ^a   Harangi, Mariann ^a   Boda, Judit ^a   Kovács, Péter ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B100; ARYLDIALKYLPHOSPHATASE; CHOLESTEROL; FIBRINOGEN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PARAOXON; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; KIDNEY FUNCTION; LIPOPROTEIN BLOOD LEVEL; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SPECTROPHOTOMETRY;

EID: 0034005522     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200019040-00005     Document Type: Article

References (34)

1. 1. Pyörälä K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiological view. Diab Metab Rev 1987; 3: 463-524
2. 2. Krolewski AS, Warram JH, Valsania P, et al. Evolving natural history of coronary artery disease in diabetes mellitus. Am J Med 1991; 90 Suppl. 2A: 56S-61S
3. 3. Parthasarathy S, Printz DJ, Boyd D, et al. Macrophage oxidation of low density lipoprotein generates a modified from recognized by the scavenger receptor. Atherosclerosis 1986; 6: 505-10
4. 4. Henriksen T, Mahoney EM, Steinberg D. Enhanced macrophage degradation of biologically modified low density lipoprotein. Atherosclerosis. 1983; 3: 149-59
5. 5. Brown MS, Goldstein JL. Scavenging for receptors. Nature 1990; 343: 508-9
6. 6. Cushing SD, Berliner JA, Valente AJ, et al. Minimally modified low density lipoprotein induces monoyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci USA 1990; 87: 5134-8
7. 7. Navab M, Imes SS, Hough GP, et al. Monocyte transmigration induced by modofication of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest 1991; 88: 2039-46
8. 8. Berliner JA, Territo MC, Sevanian A, et al. Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. J Clin Invest 1990; 85: 1260-6
9. 9. Hessler JR, Robertson Jr AL, Chisolm CM. LDL-inducedcytotoxicity and its inhibition by HDL in human vascular smooth muscle and endothelial cells in culture. Atherosclerosis 1979; 32: 213-29
10. 10. Parthasarathy S, Barnett J, Fong LG. High density lipoprotein inhibits the oxidative modification of low density lipoprotein. Biochim Biophys Acta 1990; 1044: 275-83
11. 11. Maier JAM, Barenghi L, Pagani F, et al. The protective role of high-density lipoprotein on oxidized-low-density-lipoprotein-induced U937 / endothelial cell interactions. Eur J Biochem 1994; 221: 35-41
12. 12. La Du BN. Human serum paraoxonase/arylesterase. In: Kalow W, editor. Pharmacogenetics of drug metabolism. New York: Pergamon Press, Inc., 1992: 51-91
13. 13. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low density lipoprotein. FEBS Lett 1991; 286: 152-4
14. 14. Watson AD, Berliner JA, Hama SY, et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 1995; 96: 2882-91
15. 15. Mackness MI, Arrol S, Abbott CA, et al. Is paraoxonase related to atherosclerosis. Chem Biol Interac 1993; 87: 161-71
16. 16. Paragh Gy, Seres I, Balogh Z, et al. The serum paraoxonase activity in patients with chronic renal failure and hyperlipidemia. Nephron 1998; 80: 166-70
17. 17. Paragh Gy, Asztalos L, Seres I, et al. Serum paraoxonase activity changes in uremic and kidney transplanted patients. Nephron 1999; 83: 126-31
18. 18. Saha N, Roy AC, Teo SH, et al.Influence of serum paraoxonase polymorphism on serum lipids and apolipoproteins. Clin Genet 1991; 40 (4): 277-82
19. 19. Auwerx J, Schoonjans K, Fruchart JC, et al. Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR. Atherosclerosis 1996; 124 Suppl.: S29-37
20. 20. Clauss A. Gerinnungsphysiologische schnellmerhode zur bestimmung des fibrinogenes. Acta Haematol 1957; 17: 237-46
21. 21. Abbott CA, Mackness MI, Kumar S, et al. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol 1995
22. 22. Castelli WP. The triglyceride issue: a view from Framingham. Am Heart J 1986; 112: 432-7
23. 23. Baingon D, Miller NE, Bolton CH, et al. Plasma triglyceride and high density lipoprotein cholesterol as predictors of ischaemic heart disease in British men. The Caerphilly and Speed-well Collaborative Heart Disease Studies. Br Heart J 1992; 68: 60-6
24. 24. Assmann G, Schulte H. Relation of high density lipoprotein cholesterol and triglycerides to atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol 1992; 70: 733-7
25. 25. Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 1992; 70: 733-7
26. 26. Huttunen JK, Manninen V, Manttari M, et al. The Helsinki Heart Study: central findings and clinical implications. Ann Med 1991; 23: 155-9
27. 27. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a metaanalysis of population-based prospective studies. J Cardiovasc Risk 1996; 3: 213-9
28. 28. Austin MA, Brunzell JD, Fitch WL, et al. Inheritance of low-density lipoprotein subclass patterns in familial combined hyperlipidemia. Arteriosclerosis 1990; 10: 520-30
29. 29. Wilhelmsen K, Svardsudd K, Korsan-Bengtsen K, et al. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 501-5
30. 30. Bruckert E, Gheron G, Dairou F. Comparisons de l'efficacité et de la tolerance du ciprofibrate et du gemfibrozil dans le traitement des hyperlipidemies de Type IIa et de Type II. Synthese Med 1988; 429: 14-6
31. 31. Branchi A, Rovellini A, Sommariva D, et al. Effect of three fibrate derivates and two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia. Thromb Haemost 1993; 70: 241-3
32. 32. Niort G, Bulgarelli A, Cassader M, et al. Effect of short-term treatment with bezafibrate on plasma fibrinogen, fibrinopeptide A, platelet activation and blood filterability in atherosclerotic hyperfibrinogenemic patients. Atherosclerosis 1988; 71: 113-9
33. 33. Homma Y, Ozawa H, Kobayashi T, et al. Effects of bezafibrate therapy on subfractions of plasma low-density of lecithin: cholesterol acyltransferase and cholesteryl ester transfer protein in patients with hyperlipoproteinemia. Atherosclerosis 1994; 106: 191-201
34. 34. Sommariva D, Tirrito M, Bonfiglioli D, et al. Long-term effects of hezafibrate and of a bezafibrate and cholestyramine combination on lipids and lipoprotein lipids in type IIa hypercholesterolaemic patients. Int J Clin Pharmacol Res 1986; 6: 249-53